1991
DOI: 10.1002/jps.2600800420
|View full text |Cite
|
Sign up to set email alerts
|

Development of Aqueous Parenteral Formulations for Carbamazepine through the Use of Modified Cyclodextrins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
53
0
4

Year Published

2000
2000
2018
2018

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 67 publications
(58 citation statements)
references
References 8 publications
1
53
0
4
Order By: Relevance
“…In the 78 last decade, a new Cremophor EL-free formulation of alfaxalone (3±-hydroxy-5±-79 pregnane-11,20-dione), without alfadolone, has been developed for use in small animals 80 and registered in Australia, New Zealand, South Africa and the UK (Alfaxan, Vétoquinol, 81 UK). The new formulation uses a cyclodextrin base (2-hydroxypropyl-β-cyclodextrin, 82 HPCD) as solubilizing agent and does not cause histamine release [15,16]. Alfaxalone 83 was shown to provide a rapid and smooth induction of anesthesia with rapid recovery of 84 consciousness and minimal respiratory depression at clinical doses [16,17].…”
Section: Objective: To Compare Alfaxalone and Propofol As Anesthetic mentioning
confidence: 99%
“…In the 78 last decade, a new Cremophor EL-free formulation of alfaxalone (3±-hydroxy-5±-79 pregnane-11,20-dione), without alfadolone, has been developed for use in small animals 80 and registered in Australia, New Zealand, South Africa and the UK (Alfaxan, Vétoquinol, 81 UK). The new formulation uses a cyclodextrin base (2-hydroxypropyl-β-cyclodextrin, 82 HPCD) as solubilizing agent and does not cause histamine release [15,16]. Alfaxalone 83 was shown to provide a rapid and smooth induction of anesthesia with rapid recovery of 84 consciousness and minimal respiratory depression at clinical doses [16,17].…”
Section: Objective: To Compare Alfaxalone and Propofol As Anesthetic mentioning
confidence: 99%
“…Activation by 10 mM 3a-hydroxy5a-pregnan-20-one (3a5aP) or 3a-hydroxy-5b-pregnan-20-one (3a5bP) also resulted in prominent responses (42 6 18%, 8 cells, and 45 6 19%, 4 cells, respectively). Ten micromolar is a saturating concentration for these steroids in terms of potentiation and activation (Shu et al, 2004), and is near the limit of solubility in aqueous solutions (Brewster et al, 1989). Testosterone, 17b-estradiol, dehydroepiandrosterone (DHEA), pregnenolone sulfate, and DHEA sulfate did not elicit current responses, although in some cases (e.g., in the presence of 10 mM DHEA sulfate) rebound currents following termination of steroid application were observed.…”
mentioning
confidence: 99%
“…Nevertheless, introducing hydroxypropy l groups on b -CD molecules has enabled the administration of higher doses of CDs in vivo. For instance, intravenous doses of 40 g/kg in rabbits (Irie et al 1992), 10 g/kg in monkeys (Brewster et al 1991), and 30 g (total) in humans (Carpenter et al 1995) have been administered with no adverse effects. Nevertheless, caution has to be taken since hpb -CD has been documented to induce pulmonary edema in dogs and cause occasional distress or agitation in rabbits (Carpenter et al 1995).…”
Section: Cyclodextrins and Toxicitymentioning
confidence: 99%
“…CDs have been utilized for delivery of pharmacologically active hydrophobi c compounds within polar environments. Some of the therapeutic agents so complexed include estradiol (Brewster et al 1988), testosterone (Muller and Albers 1991; Salehian et al 1995), b -sitosterol, the main dietary phytosterol (Awad et al 1996), and the antiepileptic drug carbamazepine (Brewster et al 1991(Brewster et al , 1988(Brewster et al , 1997. Apart from drug molecules, CDs are used to host sterols such as 27-OHcholesterol and cholesterol (Winegar et al 1996).…”
Section: Introduction To Cyclodextrinsmentioning
confidence: 99%